NICE, In Reversal, Rejects Ferring’s Firmagon But Backs Bayer’s Xofigo
This article was originally published in The Pink Sheet Daily
Executive Summary
The British health tech assessment agency reverses an initial restricted green light for Ferring’s prostate cancer drug after experts urged a re-evaluation. But Bayer’s prostate cancer therapy Xofigo gets a provisional go-ahead.